How Pieces Technologies’ AI is Driving Clinical Efficiency

By Michael Awood

September 14, 2023

Significant progress is being made in healthcare by Pieces Technologies Inc.

Healthcare professionals use its Artificial Intelligence (AI) platform to manage cases, plan discharges, and reduce hospital stays. Recently, the AI wrote its one-millionth clinical summary – in just seven months. This displays the role and impact that AI can have in healthcare.

The Pieces system uses advanced technology and human help to ensure high accuracy while maintaining a hallucination rate of less than 0.1%. “Hallucinations” refer to instances where the AI produces incorrect or nonsensical outputs. However, Pieces shows great promise in this area with a considerable improvement compared to existing models. This high accuracy is further evidenced by the reduced need for edits in the system’s output.

The software is a trusted tool for healthcare professionals, supporting various clinical procedures and contributing to efforts aimed at reducing patient stay duration and readmission rates.
This achievement highlights the potential of applied clinical generative AI in healthcare delivery. Pieces Technologies has committed to safety, transparency, and accountability to improve healthcare outcomes and operations.

Pieces Technologies is leading the way in redefining healthcare through AI, achieving clinical efficiency and patient care. The system is set to be implemented in pediatric hospital environments soon, further expanding its impact. This highlights the importance of AI in healthcare, not to surpass benchmarks, but to enhance patient care and clinical outcomes.

 

Cover image source: PR Newswire. Link in the reference URL

Reference url

Recent Posts

NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending natalizumab RRMS treatment o...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...

By HEOR Staff Writer

January 8, 2026

Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...